The Food and Drug Administration seems less than enthralled with Eli Lilly's
The FDA's opinion was released in documents ahead of tomorrow's advisory panel, where outside experts will make recommendations on whether florbetapir should be approved.
In the big picture, whether Lilly gets florbetapir approved doesn't matter all that much. Sure, if the FDA asks for more data, the delay might help General Electric
What investors should listen for is what the panel members think of amyloid as both a disease marker and a cause of the disease. Except for the patient representative, everyone on the panel has an M.D. or a Ph.D. after their names -- and some have both. These are influential people in the Alzheimer's disease community, and their view shouldn't be taken lightly by anyone investing in companies developing Alzheimer's disease drugs.
Both Lilly's solanezumab and rival bapineuzumab -- which is being developed by Elan
If the researchers are convinced that amyloid plaque is just a sign that the patient has Alzheimer's, but is not necessarily the cause, that could still be good news for current drugs like Aricept, which Pfizer sells with Eisai, and Forest Labs'
The FDA is offering a webcast -- details in this PDF -- so if you're interested in this high-risk, high-reward space, don't forget to watch.
Johnson & Johnson and Pfizer are Motley Fool Inside Value recommendations. Elan is a Motley Fool Rule Breakers recommendation. Johnson & Johnson is a Motley Fool Income Investor recommendation. Motley Fool Options has recommended a diagonal call position on Johnson & Johnson. The Fool owns shares of Johnson & Johnson. Motley Fool Alpha owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.